Publication:
Molecular Communication-Based intelligent dopamine rate modulator for Parkinson's disease treatment

dc.contributor.departmentNext Generation and Wireless Communication Laboratory
dc.contributor.departmentDepartment of Electrical and Electronics Engineering
dc.contributor.departmentGraduate School of Sciences and Engineering
dc.contributor.kuauthorAkan, Özgür Barış
dc.contributor.schoolcollegeinstituteCollege of Engineering
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF SCIENCES AND ENGINEERING
dc.contributor.schoolcollegeinstituteLaboratory
dc.date.accessioned2025-03-06T20:58:35Z
dc.date.issued2024
dc.description.abstractParkinson's disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to alleviate its symptoms. Due to impaired neurotransmitter-based information transmission in PD, molecular communication-based approaches can be employed as potential solutions to address this issue. Molecular Communications (MC) is a bio-inspired communication method utilizing molecules to carry information. This mode of communication stands out for developing biocompatible nanomachines for diagnosing and treating, particularly in addressing neurodegenerative diseases like PD, due to its compatibility with biological systems. This study presents a novel treatment method that introduces an Intelligent Dopamine Rate Modulator (IDRM), which is located in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum to compensate for insufficiency dopamine release in BG caused by PD. For storing dopamine in the IDRM, dopamine compound (DAC) is swallowed and crossed through the digestive system, blood circulatory system, blood-brain barrier (BBB), and brain extracellular matrix uptakes with IDRMs. Here, the DAC concentration is calculated in these regions, revealing that the required exogenous dopamine consistently reaches IDRM. Therefore, the perpetual dopamine insufficiency in BG associated with PD can be compensated. This method reduces drug side effects because dopamine is not released in other brain regions. Unlike other treatments, this approach targets the root cause of PD rather than just reducing symptoms. © 2002-2011 IEEE.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1109/TNB.2024.3456031
dc.identifier.issn1536-1241
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85204172773
dc.identifier.urihttps://doi.org/10.1109/TNB.2024.3456031
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27508
dc.keywordsDopamine
dc.keywordsDrug delivery system
dc.keywordsMolecular communication
dc.keywordsNeurotransmitter
dc.keywordsParkinson's disease
dc.language.isoeng
dc.publisherInstitute of Electrical and Electronics Engineers Inc.
dc.relation.ispartofIEEE Transactions on Nanobioscience
dc.subjectElectrical and electronics engineering
dc.titleMolecular Communication-Based intelligent dopamine rate modulator for Parkinson's disease treatment
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorBaradari Elham
local.contributor.kuauthorAkan, Özgür Barış
local.publication.orgunit1College of Engineering
local.publication.orgunit1GRADUATE SCHOOL OF SCIENCES AND ENGINEERING
local.publication.orgunit1Laboratory
local.publication.orgunit2Department of Electrical and Electronics Engineering
local.publication.orgunit2Next Generation and Wireless Communication Laboratory
local.publication.orgunit2Graduate School of Sciences and Engineering
relation.isOrgUnitOfPublicationa5d3121b-8789-4c71-84d3-12bf643bfef9
relation.isOrgUnitOfPublication21598063-a7c5-420d-91ba-0cc9b2db0ea0
relation.isOrgUnitOfPublication3fc31c89-e803-4eb1-af6b-6258bc42c3d8
relation.isOrgUnitOfPublication.latestForDiscoverya5d3121b-8789-4c71-84d3-12bf643bfef9
relation.isParentOrgUnitOfPublication8e756b23-2d4a-4ce8-b1b3-62c794a8c164
relation.isParentOrgUnitOfPublication434c9663-2b11-4e66-9399-c863e2ebae43
relation.isParentOrgUnitOfPublication20385dee-35e7-484b-8da6-ddcc08271d96
relation.isParentOrgUnitOfPublication.latestForDiscovery8e756b23-2d4a-4ce8-b1b3-62c794a8c164

Files

Original bundle

Now showing 1 - 1 of 1
Placeholder
Name:
IR05745.pdf
Size:
553.64 KB
Format:
Adobe Portable Document Format